SEC Form 4 · accession 0000899243-18-002046
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chandra Vargeese
Officer — See Remarks
Period of report
Jan 23, 2018
Accepted (ET)
Jan 25, 2018 · 8:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 23, 2018 | M | 2,000 | $2.48 | A | 11,800 | D | |
| Ordinary Shares | Jan 23, 2018 | S | 2,000 | $40.00 | D | 9,800 | D | |
| Ordinary SharesF3 | Jan 23, 2018 | A | 17,500 | $0.00 | A | 27,300 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F2 | $2.48 | Jan 23, 2018 | M | 2,000 | D | — | Mar 10, 2025 | Ordinary Shares | 2,000 | 154,542 | D |
| Share Option (right to buy)F4 | $40.05 | Jan 23, 2018 | A | 35,000 | A | — | Jan 23, 2028 | Ordinary Shares | 35,000 | 35,000 | D |
Explanation of responses
- F1The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.
- F3Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022.
- F4The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022.
Remarks
Senior Vice President, Drug Discovery